MRKMerck Sharp & Dohme LLCRunning, no new patients
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
Carcinoma, Non-Small-Cell Lung
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 614 (planned)
- Started
- Feb 6, 2023
- Main results expected
- Jan 12, 2027
- Fully finished
- Aug 23, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS)
Measured over: Up to approximately 38 months
Overall Survival (OS)
Measured over: Up to approximately 48 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05609968 · record last updated 2025-12-24 · checked 2026-11-09 15:47 UTC